Methyl 2-Cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate Is a Peroxisome Proliferator-Activated Receptor-γ Agonist That Induces Receptor-Independent Apoptosis in LNCaP Prostate Cancer Cells

Sabitha Papineni, Sudhakar Chintharlapalli, and Stephen Safe

Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas (S.P., S.S.); and Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas (S.C., S.S.)

Received August 28, 2007; accepted November 7, 2007

ABSTRACT

Methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate (β-CDDO-Me) is a synthetic analog of the naturally occurring triterpenoid glycyrrhetinic acid, which contains a 2-cyano substituent in the A-ring. β-CDDO-Me was a potent inhibitor of LNCaP prostate cancer cell growth (IC50 ~1 μM) and activated peroxisome proliferator-activated receptor γ (PPARγ), whereas analogs without the cyano group were weakly cytotoxic and did not activate PPARγ. β-CDDO-Me induced p21 and p27, down-regulated cyclin D1 protein expression, and induced two other proapoptotic proteins, namely nonsteroidal anti-inflammatory drug-activated gene-1 and activating transcription factor-3. However, induction of these responses by β-CDDO-Me was PPARγ-independent and due to activation of phosphatidylinositol-3-kinase, mitogen-activated protein kinase, and jun N-terminal kinase pathways by this compound. In contrast, β-CDDO-Me also decreased androgen receptor (AR) and prostate-specific antigen (PSA) mRNA and protein levels through kinase-independent pathways. β-CDDO-Me repressed AR mRNA transcription, whereas decreased PSA mRNA levels were dependent on protein synthesis and were reversed by cycloheximide. Thus, potent inhibition of LNCaP cell survival by β-CDDO-Me is due to PPARγ-independent activation of multiple pathways that selectively activate growth-inhibitory and proapoptotic responses.

Peroxisome proliferator-activated receptors (PPARs) are a subfamily of the nuclear receptor superfamily of ligand-activated receptors (Mangelsdorf et al., 1995). The three members of this family, PPARα, PPARγ, and PPARβ/δ, are lipid sensors and play a key role in regulating tissue-specific lipid homeostasis and metabolism (Lee et al., 2003). PPARs also play an important role in many diseases, particularly those related to obesity, metabolic disorders, cancer, and atherogenesis (Escher and Wahl, 2000; Lee et al., 2003). Endogenous ligands for PPARs include fatty acid-derived compounds and 15-deoxy-Δ12,14-prostaglandin J2 (PGJ2), which exhibits high affinity for PPARγ; however, PGJ2 may not be the endogenous ligand for this receptor because of the low cellular expression of this metabolite. Synthetic PPARγ agonists, such as the thiazolidinediones rosiglitazone and pioglitazone, are insulin-sensitizing drugs that are widely used for clinical treatment of type II diabetes.

Several different structural classes of PPARγ agonists have been characterized, and these include flavones, various indole derivatives, and triterpenoids such as 2-cyano-3,12-dioxo-17α-olean-1,9-dien-28-oic acid (CDDO) and related...
compounds (Honda et al., 1998; Rieu et al., 2002; Berger et al., 2003; Qin et al., 2004; Schopfer et al., 2005). PPARγ is overexpressed in many tumor types and cancer cell lines (Ikekoe et al., 2001), and PPARγ agonists show promise for the clinical treatment of various types of tumors (Kubota et al., 1998; Chang and Szabo, 2000; Gupta et al., 2003; Qin et al., 2004). Ligands for this receptor typically inhibit G1/G0- to S-phase progression, and this is accompanied by down-regulation of cyclin D1 expression and induction of the cyclin-dependent kinase inhibitors p27 or p21. Research from our laboratory has identified a series of 1,1-bis(3'-indolyl)-1-(p-substituted phenyl)methanes [methylene-substituted diindolyl-methanes (C-DIMs)], which inhibit cancer cell and tumor growth (Chintharlapalli et al., 2004, 2005a, 2007b; Hong et al., 2004; Qin et al., 2004; Abdelrahim et al., 2006) through both receptor-dependent and independent pathways, and similar observations have been reported for other PPARγ agonists (Clay et al., 2002; Konopleva et al., 2004; Samudio et al., 2005; Yang et al., 2006).

A new class of synthetic PPARγ agonists has been derived from glycerethetic acid (GA), a major triterpenoid acid found in licorice extracts. Methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate (β-CDODA-Me) is a 2-cyano derivative of GA and has the same oleanonic acid pentacyclic triterpene backbone structure as CDDO, which is also a 2-cyano derivative of oleanolic acid (Honda et al., 1998). However, there are major structural differences between CDDO and CDDO with respect to the position of the carboxylic acid group in the E-ring, the position of the double bonds and keto group in the C-ring. We reported recently that the 18α and 18β isomers of CDODA-Me activate PPARγ in colon cancer cells and induced both cavelon-1 and Krüppel-like Factor-4 through receptor-dependent pathways (Chintharlapalli et al., 2007a). In this study, we investigated the effects of β-CDODA-Me on the proliferation of LNCaP prostate cancer cells, and the IC50 value for growth inhibition was approximately 1 μM. In contrast to studies in colon cancer cells, β-CDODA-Me had minimal effects on cavelon-1 or Krüppel-like Factor-4 expression in LNCaP cells. The proapoptotic and growth-inhibitory effects of β-CDODA-Me in LNCaP cells were associated with the induction of p21 and p27 expression, down-regulation of cyclin D1, and induction of nonsteroidal anti-inflammatory drug-activated gene 1 (NAG1). β-CDODA-Me also decreased androgen receptor (AR) and prostate-specific antigen (PSA) protein and RNA expression, and all of these responses were PPARγ-dependent. Thus, β-CDODA-Me, a PPARγ agonist, inhibited growth and induced apoptosis in LNCaP cells through activation of multiple receptor-independent pathways, including ablation of AR gene expression.

Materials and Methods

Cell Lines. LNCaP, PC3, and DU145 human prostate carcinoma cells were obtained from American Type Culture Collection (Manassas, VA). Fetal bovine serum was obtained from JRH Biosciences (Lenexa, KS). LNCaP, PC3, and DU145 cells were maintained in RPMI 1640 medium (Sigma Chemical, St. Louis, MO) supplemented with 0.22% sodium bicarbonate, 0.011% sodium pyruvate, 0.45% glucose, 0.24% HEPES, 10% FBS, and 10 mM 100X antibiotic/antimycotic solution (Sigma). Cells were maintained at 37°C in the presence of 5% CO2.

Antibodies and Reagents. Antibodies for poly(ADP-ribose) polymerase, cyclin D1, p27, FKBP51, AR, ATF3, Akt, and cavelon-1 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). PSA was obtained from Dako Denmark A/S (Glostrup, Denmark); NAG1 was purchased from Upstate Biotechnology (Charlottesville, VA); and EGR-1, pAKT, phosphorylated extracellular signal-regulated kinase, extracellular signal-regulated kinase, pJNK, and JNK were obtained from Cell Signaling Technology Inc. (Danvers, MA). Monoclonal β-actin antibody and dihydrotestosterone were purchased from Sigma-Aldrich. Reporter lysis buffer and luciferase reagent for luciferase studies were purchased from Promega (Madison, WI). β-Galactosidase reagent was obtained from Tropix (Bedford, MA), and Lipofectamine reagents were supplied by Invitrogen (Carlsbad, CA). Western blotting chemiluminescence reagents were from PerkinElmer Life and Analytical Sciences (Waltham, MA). The PPARγ antagonist T007 was prepared in this laboratory, and the synthesis of the GA derivatives has been described previously (Chintharlapalli et al., 2007a).

Cell Proliferation and DNA Fragmentation Assays. LNCaP prostate cancer cells (2 × 106/well) were added to 12-well plates and allowed to attach for 24 h. The medium was then changed to DMEM/Ham’s F-12 media containing 2.5% charcoal-stripped FBS, and either vehicle (DMSO) or the indicated compounds were added. Fresh medium and indicated compounds were added every 48 h, and cells were then trypsinized and counted at 2, 4, and 6 days using a Coulter Z1 cell counter (Beckman Coulter, Fullerton, CA). Each experiment was done in triplicate, and results are expressed as means ± S.E. for each set of three experiments. The DNA fragmentation assay was performed using an Apoptotic DNA ladder extraction kit (BioVision, Mountain View, CA) according to the manufacturer’s protocol.

Transfections. The Gal4 reporter construct containing 5×Gal4 response elements (pGal4) was kindly provided by Dr. Marty Mayo (University of North Carolina, Chapel Hill, NC). The Gal4DBD-PPARγ construct was a gift of Dr. Jennifer L. Oberfield (Glaxo SmithKline, Research Triangle Park, NC). The PPRE-luc construct contains three tandem PPReVs with a minimal TATA sequence linked to the luciferase gene in pGL2. The AR-luc construct containing the −5400 to +580 region of the androgen receptor promoter was provided by Dr. Donald J. Tindall (Mayo Clinic, Rochester, MN), and the PSA-luc construct containing the 5.8-kilobase region of the PSA promoter was provided by Dr. Hong-Wu Cheng (University of California, Davis, CA). LNCaP cells (1 × 106) were seeded in 12-well plates in DMEM/Ham’s F-12 media supplemented with 2.5% charcoal-stripped FBS and grown overnight. Transient transfections were performed using Lipofectamine reagent (Invitrogen) according to the protocol provided by the manufacturer. Transfection studies were performed using 0.4 μg of Gal4Luc, 0.04 μg of β-galactosidase, 0.04 μg of Gal4DBD-PPARγ, 0.4 μg of AR-luc, and 0.3 μg of PSA-luc. Six hours after transfection, the transfection mix was replaced with complete media containing either vehicle (DMSO) or the indicated ligand for 20 to 22 h. Cells were then lysed with 100 μl of 1× reporter lysis buffer, and 30 μl of cell extract was used for luciferase and β-galactosidase assays. A Lumiconic luminometer (PerkinElmer Life and Analytical Sciences) was used to quantify luciferase and β-galactosidase activities, and the luciferase activities were normalized to β-galactosidase activity.

Fluorescence-Activated Cell Sorting Analysis. LNCaP cells were treated with either the vehicle (DMSO) or the compound for 24 h. Cells were trypsinized, centrifuged, and resuspended in staining solution containing 50 μg/ml propidium iodide, 4 mM sodium citrate, and 30 U/ml RNase. After incubation at room temperature for 1 h, cells were analyzed on a FACSVantage SE DiVa (BD Biosciences, San Jose, CA), using BD FACS DIVA software, version 4.1.1. Propidium iodide (PI) fluorescence was collected through a 610 SP bandpass filter, and list mode data were acquired on a minimum of 50,000 single cells defined by a dot plot of PI width versus PI area.

Downloaded from mammpharmacology.aspetjournals.org at ASPET Journals on June 21, 2017
Data analysis was performed in BD FACSDiva software version 4.1.1 using PI width versus PI area to exclude cell aggregates. **Real-Time PCR.** Total RNA was isolated using the RNeasy Protect Mini kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. RNA was eluted with 30 μl of RNase-free water and stored at −80°C. RNA was reverse-transcribed using Superscript II reverse transcriptase (Invitrogen) according to the manufacturer's protocol. cDNA was prepared from the LNCaP cell line using a combination of oligo(dT)18 and dNTP mix (Applied Biosystems, Foster City, CA) and Superscript II (Invitrogen). Each PCR was carried out in triplicate in a 25-μl volume using SYBR Green Master mix (Applied Biosystems) for 15 min at 95°C for initial denaturing, followed by 40 cycles of 95°C for 30 s and 60°C for 1 min in the ABI Prism 7700 sequence detection system (Applied Biosystems). The ABI Dissociation Curves software was used after a brief thermal protocol (95°C for 15 s and 60°C for 20 s, followed by a slow ramp to 95°C) to control for multiple species in each PCR amplification. The comparative CT method was used for relative quantitation of samples. Values for each gene were normalized to expression levels of TATA-binding protein. Primers were purchased from Integrated DNA Technologies (Corvalle, IA). The sequences of the primers used for reverse transcription-PCR were as follows: AR: forward, 5′-GTA CCC TGG CCG CAT GGT-3′ and reverse, 5′-ATT TCG CTT TTG ACA CA-3′; PSA: forward, 5′-GGA CCC TGG CGG CAT GGT-3′, and reverse, 5′-GCA TTC GGA CCC CAC CA-3′. The ABI’s protocol. RNA was eluted with 30 μl of RNase-free water and stored at 4°C. RNA was reverse-transcribed using Superscript II (Invitrogen) and on the expression of FKBP51 and PSA, two androgen-responsive genes. Results were similar to those observed in colon cancer cells (Chintharlapalli et al., 2007a) and demonstrate the importance of 2-cyano substituents in mediating the cytotoxicity of GA derivatives. Figure 1B shows that decreased LNCaP cell survival induced by β-CDDOA-Me was not affected after cotreatment with the PPARγ antagonist T007, suggesting that the cytotoxicity of this compound was receptor-independent. β-CDDOA-Me was also cytotoxic to androgen-insensitive PC3 and DU145 prostate cancer cells (Fig. 1C). The induction of PPARγ-dependent transactivation by β-CDDOA-Me was also investigated in LNCaP cells transfected with PPARγ-GAL4/GAL4-Luc or PPRe-Luc constructs and treated with 1 to 5 μM concentrations. β-CDDOA-Me significantly induced luciferase activity (Fig. 1D), and in cells cotreated with β-CDDOA-Me plus 10 μM T007 (a PPARγ antagonist), there was significant inhibition of induced transactivation. In contrast, β-DODA-Me did not activate PPARY (data not shown), demonstrating the requirement for the 2-cyano substituent to confer PPARY agonist activity on the GA derivative.

PPARY agonists typically modulate the expression of one or more of the cell cycle proteins p27, p21, and cyclin D1, and Fig. 2A illustrates the effects of 1 to 5 μM β-CDDOA-Me on the expression of these proteins in LNCaP cells. There was a concentration-dependent induction of p27 and p21 and a decrease in cyclin D1 proteins and retinoblastoma protein phosphorylation in cells treated with β-CDDOA-Me alone, and similar results were observed in cells cotreated with the PPARY antagonist T007 and β-CDDOA-Me (Fig. 2B), suggesting that these responses were PPARY-independent. FACS analysis of LNCaP cells treated with different concentrations of β-CDDOA-Me indicated that 1 μM β-CDDOA-Me did not affect the percentage of cells in G0/G1, S, or G2/M, whereas at higher concentrations, the percentage of cells in these phases of the cell cycle decreased (Fig. 2C). β-CDDOA-Me induced a concentration-dependent increase in the percentage of apoptotic sub-G1 LNCaP cells, and the proapoptotic effects of this compound were also observed in PC3 and DU145 cells (Fig. 2D), in which β-CDDOA-Me induced caspase-dependent PARP cleavage. Thus, the overall cytotoxicity of β-CDDOA-Me in prostate cancer cells was associated with both inhibition of growth and induction of apoptosis.

**Induction of Proapoptotic Responses by β-CDDOA-Me.** NAG-1 and ATF-3 are proapoptotic proteins induced by PPARY agonists, and results in Fig. 3A show that 1 to 5 μM β-CDDOA-Me induced NAG-1 and ATF-3, which are often coinduced, and this was accompanied by caspase-dependent PARP cleavage, DNA fragmentation, and decreased bcl2 expression in LNCaP cells. In addition, the DNA laddering response was not affected after cotreatment with the PPARY antagonist T007 (Fig. 3B). In LNCaP cells cotreated with β-CDDOA-Me plus T007 (Fig. 3C), the induced responses were not inhibited by the PPARY antagonist, indicating that induction of these proapoptotic responses was receptor-independent. Previous studies show that different structural classes of PPARY agonists down-regulate AR expression in LNCaP cells, and this response can also result in the activation of apoptosis (Yang et al., 2006; Chintharlapalli et al., 2007b). Figure 3D summarizes the effects of β-CDDOA-Me on AR expression in the presence or absence of 10 nM DHT and on the expression of FKBP51 and PSA, two androgen-responsive genes in LNCaP cells. DHT increases expression of AR as a result of stabilization of the receptor and induces both androgen-responsive FKBP51 and PSA genes; in cells...
Fig. 1. Effects of β-CDODA-Me and related compounds on LNCaP cell survival and activation of PPARγ. Cell survival of LNCaP (A and B), PC3, and DU145 (C) cells. Prostate cancer cells were treated with different concentrations of β-DODA, β-DODA-Me, or β-CDODA-Me alone or in combination with 5 μM T007 (C) for 96 h, and the percentage of cell survival relative to DMSO (solvent control set at 100%) was determined as described under Materials and Methods. Results are expressed as means ± S.E. for three separate determinations for each treatment group, and significantly (p < 0.05) decreased survival is indicated (*). D, β-CDODA-Me activates PPARγ. LNCaP cells were treated with β-CDODA, T007, or their combination, transfected with PPARγ-GAL4/pGAL4 or PPRE-luc, and luciferase activity determined as described under Materials and Methods. Results are expressed as means ± S.E. for three replicate determinations for each treatment group, and significant (p < 0.05) induction by β-CDODA-Me (*) and inhibition after cotreatment with T007 (**) are indicated.
treated with 1 to 5 μM β-COODA-Me, there was a concentration-dependent decrease in AR, PSA, and FKBP51 expression in the presence or absence of DHT. In addition, down-regulation of AR, PSA, and FKBP51 proteins in LNCaP cells treated with β-COODA-Me was not affected by cotreatment with the PPARγ antagonist T007 or the proteasome inhibitor MG132 (Fig. 3E). In contrast, β-COODA-Me-dependent degradation of cyclin D1 was inhibited after cotreatment with MG132, and these observations are similar to those reported for other PPARγ agonists that induce proteasome-dependent degradation of cyclin D1 (Chintharlapalli et al., 2004, 2005a,b). These results clearly show that β-COODA-Me decreases expression of androgen-responsive genes and AR through PPARγ-independent pathways. The down-regulation of AR in cells treated with β-COODA-Me is consistent with the induction of apoptosis by this compound because decreased AR expression by small inhibitory RNAs in LNCaP cells also induces apoptosis (Liao et al., 2005).

β-COODA-Me Induced Kinase-Dependent Activation of Proapoptotic/Growth Inhibitory Pathways. Previous studies show that NAG-1 is induced by some PPARγ agonists and other cytotoxic compounds in colon cancer cells (Baek et al.,

![Fig. 2. β-COODA-Me modulates the cell cycle and cell cycle genes and induces apoptosis in prostate cancer cells. Modulation of cell cycle genes by β-COODA-Me alone (A) and in combination with T007 (B). Cells were treated as indicated for 24 h, and whole-cell lysates were analyzed by Western blot analysis as described under Materials and Methods. C, cell cycle progression. LNCaP cells were treated with DMSO and different concentrations of β-COODA-Me for 24 h and analyzed for the percentage of distribution of cells in different phases of the cell cycle by FACS analysis as described under Materials and Methods. Results are expressed at means ± S.E. for three replicate determinations, and significant (p < 0.05) changes (compared with DMSO group) are indicated by an asterisk. D, induction of PARP cleavage. PC3 and DU145 cells were treated for 24 h with different concentrations of β-COODA-Me, and whole-cell lysates were analyzed by Western blots as described under Materials and Methods.](https://doi.org/10.1093/molpharm/557.557.557)
Fig. 3. β-CDODA induces apoptotic pathways and decreases androgen-responsiveness in LNCaP cells. β-CDODA-Me alone (A) and in combination with T007 (B and C) induces proapoptotic pathways. LNCaP cells were treated as indicated for 24 h, and whole-cell lysates were analyzed by Western blot analysis as described under Materials and Methods. β-CDODA-Me-induced DNA fragmentation (A and B) was also determined as described. Effects of β-CDODA-Me alone and in combination with DHT or T007 (D) or MG132 (E) on AR and androgen-responsive proteins. LNCaP cells were treated with DMSO or the various compounds for 24 h, and whole-cell lysates were analyzed by Western blot analysis as described under Materials and Methods.
2003, 2005; Chintharlapalli et al., 2005a) through PI3K-dependent activation of EGR-1, which acts as a transacting factor to induce NAG-1 expression. Figure 4A summarizes the time-dependent induction of EGR-1, ATF-3, and NAG-1 by 2.5 µM β-CDODA-Me, and the induction responses followed a similar time course, whereas EGR-1-dependent induction of NAG-1 in colon cancer cells is associated with the increased expression of EGR-1 before induction of NAG-1 (Baek et al., 2005; Chintharlapalli et al., 2005a). Previous studies show that NAG-1 induction is kinase-dependent (Baek et al., 2005; Chintharlapalli et al., 2005a), and results in Fig. 4B show that 2.5 µM β-CDODA-Me induces activation of the JNK (pJNK), PI3K (pAkt), and MAPK (pErk) pathways. Maximal activation of JNK and PI3K was observed after 8 and 8 to 12 h, respectively,

Fig. 4. β-CDODA-Me induces proapoptotic proteins and kinases. Induction of NAG-1, ATF3, and Egr-1 (A) and kinases (B) by β-CDODA-Me. LNCaP cells were treated with 2.5 µM β-CDODA-Me, and whole-cell lysates isolated at different times after treatment were analyzed by Western blot analysis as described under Materials and Methods. Effects of kinase inhibitors on proapoptotic responses (C) and quantitation of NAG-1 and ATF3 expression (D). LNCaP cells were treated with 2.5 µM β-CDODA alone or in combination with various kinase inhibitors, and after 24 h, whole-cell lysates were analyzed by Western blot analysis. Levels of NAG-1 and ATF3 proteins (normalized to β-actin) (D) are means ± S.E. for three separate determinations for each treatment group, and significantly (p < 0.05) decreased levels after cotreatment with a kinase inhibitor are indicated (***).
whereas pErk activation remained elevated for 24 h. The effects of inhibitors of MAPK (PD98059), PI3K (LY294002), protein kinase C (GF109203X), and JNK (SP600125) on induction of NAG-1 and ATF3, and decreased expression of AR, PSA, and FKBP51 was also investigated in LNCaP cells treated with 2.5 μM β-CDODA-Me (Fig. 4C). Both PD98059 and LY294002 in-

![Image](Fig. 5. β-CDODA-Me induction of p21 is MAPK-dependent. A, effects of kinase inhibitors on induction of p21. LNCaP cells were treated with DMSO, 2.5 μM β-CDODA-Me alone or in combination with kinase inhibitors for 24 h, and whole-cell lysates were analyzed by Western blot analysis as described under Materials and Methods. B, β-CDODA-Me activates p21 promoter constructs. LNCaP cells were transfected with p21 promoter constructs, treated with DMSO or different concentrations of β-CDODA-Me, and luciferase activity was determined as described under Materials and Methods. Results are means ± S.E. for three separate determinations for each treatment group, and significant (p < 0.05) induction of activity is indicated (+). C, inhibition by PD98059. Cells were transfected with p21-luc(101), treated with DMSO or β-CDODA-Me alone or in combination with 10 μM PD98059. Results are expressed as means ± S.E. for three separate determinations for each treatment group, and significant (p < 0.05) induction by β-CDODA-Me (+) and inhibition after cotreatment with PD98059 (**) are indicated.)
hibited the induction of NAG-1 by β-CDOCKER-Me. However, the JNK inhibitor SP600125 was the most potent inhibitor of ATF-3 induction (Fig. 4, C and D). In contrast, decreased expression of AR, PSA, and FKBP51 in LNCaP cells treated with β-CDOCKER-Me was unaffected by kinase inhibitors. CDDO and related compounds also induce activation of JNK in leukemia cells through increased reactive oxygen species (Ikeda et al., 2003), and Fig. 4E illustrates the effects of β-CDOCKER-Me on activation of JNK and ATF3 after cotreatment with the antioxidant NAC. Induction of JNK phosphorylation and ATF3 by β-CDOCKER-Me was inhibited after cotreatment with NAC, demonstrating that like CDDO (Ikeda et al., 2003), β-CDOCKER-Me activates JNK through increased oxidative stress.

These results suggest that the underlying pathways associated with the growth-inhibitory/proapoptotic pathways induced by β-CDOCKER-Me in LNCaP cells are due in part to activation of kinases. Therefore, the effects of kinase inhibitors on modulation of cell cycle proteins by β-CDOCKER-Me were also investigated, and the down-regulation of cyclin D1 and induction of p21 were partially blocked in cells cotreated with the MAPK inhibitor PD98059 (Fig. 5A); MAPK-dependent activation of p21 has been observed previously (De Siervi et al., 2004). Results in Fig. 5B show that the 1 to 5 μM β-CDOCKER-Me also induces luciferase activity in LNCaP cells transfected with constructs containing −2325 to +8 [p21-Luc (Fl)], −124 to +8 [p21-Luc (−124)], −101 to +8 [p21-Luc (−101)], and −60 to +8 [p21-Luc (−60)] p21 promoter inserts. The latter three constructs contain the six proximal GC-rich sites (VI-I), and the results of the transfection studies suggest that these GC-rich sites are necessary for β-CDOCKER-Me-induced transactivation. Deletion analysis of the p21 promoter indicates that loss of inducibility [i.e., p21-luc(60)] is associated with loss of GC-rich sites IV and III, which are essential for MAPK-dependent activation of p21 by β-CDOCKER-Me. The role of MAPK in activation of the p21 promoter was confirmed in LNCaP cells transfected with p21-luc(101); β-CDOCKER-Me induced luciferase activity, and cotreatment with the MAPK inhibitor PD98059 inhibited this response (Fig. 5C). These results show that the induction of p21 and the proapoptotic NAG-1 protein by β-CDOCKER-Me were related to the activation of MAPK and PI3K but were independent of PPARγ (Fig. 2, B and C).

**β-CDOCKER-Me Differentially Decreased AR and PSA Gene Expression in LNCaP Cells.** β-CDOCKER-Me decreases expression of AR, PSA, and FKBP51 protein levels through proteasome and PPARγ-independent pathways (Fig. 3, D and E), and these responses are also not modulated by kinase inhibitors (Fig. 4C). The results in Fig. 6A show that β-CDOCKER-Me also decreases AR mRNA levels after treatment for 18 h, and cotreatment with the PPARγ antagonist T007 did not affect mRNA levels confirming the β-CDOCKER-Me-induced down-regulation of AR mRNA levels was also PPARγ-independent. Similar results were obtained in LNCaP cells treated with β-CDOCKER-Me alone or in the presence

**Fig. 6.** β-CDOCKER-Me decreases AR gene expression. Effects of T007 (A) and cycloheximide (B) on β-CDOCKER-Me-dependent effects on AR gene expression. LNCaP cells were treated with β-CDOCKER-Me alone or in combination with T007 or cycloheximide for 18 h, and AR mRNA levels were determined by real-time PCR as described under Materials and Methods. Similar results were observed after treatment for 12 h (data not shown). C, β-CDOCKER-Me decreases AR promoter activity. LNCaP cells were transfected with AR-luc, treated with DMSO or β-CDOCKER-Me, and luciferase activity was determined as described under Materials and Methods. Results are means ± S.E. for three separate experiments for each treatment group, and a significant (p < 0.05) decrease in activity is indicated (*). D, time-dependent effects of β-CDOCKER-Me on AR, Sp1, and PARP (cleaved). LNCaP cells were treated with DMSO or β-CDOCKER-Me for up to 24 h, and whole-cell lysates were analyzed by Western blot analysis as described under Materials and Methods.
of the protein synthesis inhibitor cycloheximide (10 μg/ml) (Fig. 6B); cycloheximide did not modulate the effects of β-CDOCKER-Me, suggesting that an induced inhibitory protein(s) does not mediate the effects of β-CDOCKER-Me on AR mRNA expression. β-CDOCKER-Me also decreased luciferase activity in LNCaP cells transfected with the AR-Luc construct that contains the -5400 to +580 region of the AR promoter linked to the luciferase gene (Fig. 6C). The results indicate that β-CDOCKER-Me inhibits AR transcription without the parallel induction of inhibitory transacting factors. Recent studies suggest that AR down-regulation of a PPARγ-inactive thiazolidinedione analog was due to down-regulation of Sp1 protein (Yang et al., 2007). Results in Fig. 6D show that β-CDOCKER-Me induces a time-dependent induction of PARP cleavage and a decrease of both AR and Sp1.

PSA protein expression is also decreased in LNCaP cells treated with β-CDOCKER-Me (Fig. 3D), and similar effects were observed for PSA mRNA levels after treatment for 18 h; these responses were not inhibited after cotreatment with the PPARγ antagonist T007 (Fig. 7A). However, β-CDOCKER-Me-induced down-regulation of PSA mRNA levels after treatment for 18 h was significantly inhibited after cotreatment with cycloheximide (Fig. 7B). In addition, β-CDOCKER-Me inhibited transactivation in LNCaP cells transfected with the PSA-Luc construct (contains 5.85 kilobases of the PSA promoter insert) (Fig. 7C), and similar results were obtained for DHT-induced luciferase activity (Fig. 7D). Thus, in contrast to results obtained for AR, β-CDOCKER-Me inhibits PSA expression through induction of inhibitory transacting factors, and the mechanisms associated with the decreased PSA expression and the cis-elements important for this response are currently being investigated.

Discussion

PPARγ agonists have been investigated extensively in both in vitro and in vivo cancer models for their potential applications in cancer chemotherapy (Honda et al., 1998; Escher and Wahli, 2000; Berger et al., 2003; Qin et al., 2004). PPARγ agonists inhibit prostate cancer cell and tumor growth (Kubota et al., 1998; Moretti et al., 2001; Segawa et al., 2002; Chintharlapalli et al., 2007b), and the fact that approximately 40% of patients with prostate cancer carry hemizygous deletions of PPARγ (Mueller et al., 2000) suggests that this receptor may serve as a tumor suppressor gene for prostate cancer. However, in animal studies using the transgenic adenocarcinoma mouse prostate model with hemizygous deletion in PPARγ, it was shown that the loss of receptor
expression did not enhance or inhibit prostate tumor development in these animals (Saez et al., 2003). Thus, at least in the transgenic adenocarcinoma mouse prostate mouse model, PPARγ does not seem to act as a tumor suppressor gene.

One of the perplexing problems with PPARγ agonists is that although these compounds inhibit cancer cell and tumor growth, their mechanisms of action are both receptor-dependent and -independent in different cancer cell lines. For example, PGJ2, troglitazone, and PPARγ-active C-DIMs induce NAG-1 in HCT-116 colon cancer cells; however, only induction by PGJ2 is inhibited by a PPARγ antagonist (Baek et al., 2003; Chintharlapalli et al., 2005a). Cavelonin-1 is induced by C-DIM compounds and CDDO in colon cancer cell lines, and this response is inhibited after cotreatment with PPARγ antagonists (Chintharlapalli et al., 2004, 2005b). In contrast, C-DIMs decreased caveolin-1 expression in LNCaP cells, and this response was PPARγ-independent (Chintharlapalli et al., 2007b).

β-CDODA-Me is a triterpenoid acid that contains an oleanolic acid backbone structure similar to that of CDDO and CDDO-Me (methyl ester) (Honda et al., 1998), but there are important structural differences in the C-, D-, and E-rings that differentiate between these compounds. However, for both compounds, the 2-cyano group was necessary for the activation of PPARγ.

In this study, we investigated the growth-inhibitory and proapoptotic effects of β-CDODA-Me in LNCaP cells and the role of PPARγ in mediating these responses. β-CDODA-Me was a more potent inhibitor of LNCaP cell growth than analogs (β-DODA and β-DODA-Me) that did not contain a 2-cyano substituent (Fig. 1A). Moreover, β-CDODA-Me decreased survival of androgen-insensitive PC3 and DU145 cells (Fig. 1C) and also induced apoptosis in these cells (Fig. 2D). β-CDODA-Me activated PPARγ-dependent transactivation in transient transfection studies in LNCaP cells (Fig. 1D), and compounds without the CN-group were inactive (data not shown) as reported previously for these analogs in colon cancer cells (Chintharlapalli et al., 2007a). β-CDODA-Me induced p27 expression and downregulated levels of cyclin D1 protein (Fig. 2, A and B). Similar effects were reported previously for C-DIMs in LNCaP cells (Chintharlapalli et al., 2007b), and the effects of both compounds were receptor-independent; however, β-CDODA-Me-induced responses were observed at lower concentrations (1–2.5 μM) than the C-DIM compounds (7.5–10 μM). C-DIMs did not induce p21 in LNCaP cells (Chintharlapalli et al., 2007b), whereas β-CDODA-Me induced p21 protein, and this response was not inhibited after cotreatment with PPARγ antagonist T007 (Fig. 2B). Differences between PPARγ-active C-DIMs and β-CDODA-Me in their induction of p21 in LNCaP cells was due to activation of MAPK signaling by the latter compound (Fig. 2B), which was required for the induction of p21 protein (Fig. 5A) and activation of the p21 promoter (Fig. 5C). This is a novel pathway for induction of p21 in LNCaP cells; however, previous studies in other cell lines have demonstrated MAPK-dependent induction of p21 expression (De Siervi et al., 2004).

NAG-1 and ATF3 are growth-inhibitory and proapoptotic proteins (Hartman et al., 2004; Jang et al., 2006), and previous studies with PPARγ agonists report both receptor-dependent and -independent induction of NAG-1 (Baek et al., 2003; Chintharlapalli et al., 2005a,b). Induction of NAG-1 and ATF3 by β-CDODA-Me in LNCaP cells was also PPARγ-independent. Both PI3K and MAPK inhibitors blocked the induction of NAG-1; however, the JNK inhibitor SP600125 was the most potent inhibitor of ATF3 (but not NAG-1) induction. The inhibitory effects of SP600125 are consistent with previous studies showing that homocysteine also induces ATF3 in vascular cells through activation of JNK, which activates c-jun and ATF3 through an activator protein-1 site in the ATF3 promoter (Cheng et al., 2006). The structurally related triterpenoid CDDO induces oxidative

---

Fig. 8. β-CDODA-Me-dependent activation of kinases and kinase-dependent genes and repression of AR and PSA.
stress in leukemia and pancreatic cancer cells (Ikeda et al., 2003; Samudio et al., 2005), and this is correlated with prooxidant-dependent induction of JNK phosphorylation and other responses that are inhibited by antioxidants such as NAC (Ikeda et al., 2003). Similar results were observed in this study where NAC also inhibits β-CDDOA-Me-dependent activation of JNK and induction of ATF3 (Fig. 4E). The kinase-dependent induction of NAG-1 has been reported previously, and these effects are both structure- and cell context-dependent. For example, troglitazone and PPARγ-active C-DIMs induce NAG-1 in HCT116 colon cancer cells through rapid activation of Egr-1, which subsequently activates NAG-1 through direct interaction with the proximal region of the NAG-1 promoter (Chintharlapalli et al., 2005a). However, this induction response is MAPK-dependent for troglitazone and PI3K-dependent for the C-DIM compound. In this study, the time-dependent induction of both EGR-1 and NAG-1 are similar in LNCaP cells (Fig. 4A), and inhibition of NAG-1 expression is observed with both PI3K and MAPK inhibitors (Fig. 4B). This may involve cooperative interactions of both kinase pathways for the induction of NAG-1 by β-CDDOA-Me in LNCaP cells, and mechanisms for these responses are currently being investigated. It is interesting that induction of NAG-1 by PPARγ-active C-DIMs in LNCaP cells was inhibited only by the MAPK inhibitor PD98059 (Chintharlapalli et al., 2007b), suggesting differences between β-CDDOA-Me and C-DIMs in the same cell line. Thus, induction of both NAG-1 and ATF3 in LNCaP cells is differentially induced by two PPARγ agonists, C-DIMs and β-CDDOA-Me, through receptor-dependent activation of different kinase pathways.

Recent reports show that in LNCaP cells, AR knockdown by RNA interference results in apoptosis (Liao et al., 2005), and stable knockdown using short hairpin RNAs for AR results in decreased AR and PSA expression and inhibition of tumor growth in vivo (Cheng et al., 2006). Like β-CDDOA-Me, AR and PSA expressions are also decreased by C-DIMs and troglitazone in LNCaP cells, and 3,3′-diindolylmethane (DIM) also decreases expression of both genes and proteins (Bhuiyan et al., 2006; Li et al., 2007). Troglitazone differentially decreases PSA and AR expression at relatively low (IC50 ≤ 10 μM) and high (IC50 ~40 μM) concentrations, respectively (Yang et al., 2006). In contrast, C-DIMs decreased AR and PSA mRNA, protein and reporter gene activity in cells transfected with PSA-Luc and AR-Luc constructs over a narrow range of concentrations (7.5–10 μM) (Chintharlapalli et al., 2007b), and similar results were observed for β-CDDOA-Me (1–2.5 μM) in this study (Figs. 6 and 7). Moreover, cycloheximide reversed the β-CDDOA-Me- and C-DIM-dependent down-regulation of PSA but not AR mRNA levels, suggesting a similar mechanism of action for both compounds. One study reported that DIM inhibited nuclear uptake of AR in LNCaP cells (Le et al., 2003), and like β-CDDOA-Me, DIM also decreased AR and PSA expression in LNCaP and androgen-insensitive C4-2B cells (Bhuiyan et al., 2006; Li et al., 2007). However, there are several differences between the pathways associated with down-regulation of these genes by β-CDDOA-Me and DIM, and this includes the pivotal role for DIM as an inhibitor of phospho-Akt (Bhuiyan et al., 2006; Li et al., 2007), whereas β-CDDOA-Me induces phospho-Akt (Fig. 4B), and the PI3K inhibitor LY294002 does not affect β-CDDOA-Me-dependent down-regulation of AR, PSA, or FKBP51 (Fig. 4C) or induction of p21 or p27 (Fig. 5A).

A recent report indicated that decreased AR expression in LNCaP cells treated with a PPARγ-inactive thiazolidinedione-one derivative was due to proteasome-dependent degradation of Sp1 (Yang et al., 2007). Our results also show a parallel decrease of AR and Sp1 in LNCaP cells treated with β-CDDOA-Me (Fig. 6D); however, down-regulation of AR was not reversed by a proteasome inhibitor (Fig. 3E), and the mechanism of this response is currently being investigated.

Loss of AR by RNA interference results in the induction of apoptosis in LNCaP cells (Liao et al., 2005). In contrast, 2.5 μM β-CDDOA-Me rapidly induces PARP cleavage and apoptosis in LNCaP cells before decreased AR expression (Fig. 6D) demonstrating that apoptotic pathways activated by β-CDDOA-Me in LNCaP cells are not associated with loss of AR, and the proapoptotic mechanisms are currently being investigated.

Results of this study demonstrate that β-CDDOA-Me is a potent inhibitor of LNCaP cell growth and induces proapoptotic responses through activation of kinases, which differentially activate ATF3, NAG-1, and p21. In contrast, decreased expression of AR and PSA are kinase-independent and occur through different pathways (Fig. 8). β-CDDOA-Me, C-DIMs, DIM, and troglitazone exhibited both differences and similarities in their modes of action in LNCaP cells, although all of these compounds decreased expression of AR and PSA. The growth-inhibitory and proapoptotic effects of β-CDDOA-Me were primarily PPARγ-independent in LNCaP cells (Figs. 1B and 3). β-CDDOA-Me also decreased survival and induced apoptosis in androgen-insensitive PC3 and DU145 prostate cancer cells (Figs. 1C and 2D), and similar results have been observed for other PPARγ agonists. It is apparent that β-CDDOA-Me decreases survival and induces apoptosis through multiple pathways, including its potent antiandrogenic activity in LNCaP cells. The successful applications of β-CDDOA-Me and other such compounds for single or combined prostate cancer chemotherapies will require insights on their mechanisms of action and prostate cancer cell context-dependent similarities and differences in activating critical pathways such as those illustrated in Fig. 8.

References


